ITW

NOV 1 3 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gosse B. Bruinsma

Serial No.: 10/593,215

Filed: October 4, 2006

For: ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS USEFUL IN THE TREATMENT OF COGNITIVE

DISORDERS

Confirmation No.: 7046

Examiner: Unknown

Group Art Unit: 1614

Attorney Docket No.: 3154-6311.1US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

November 7, 2007

.

Betty Vowles

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Serial No.: 10/593,215

Foreign Patent Documents

Document No.	Publication Date	<u>Patentee</u>
WO 94/12176	06-09-1994	The United States of America
WO 03/082270 A1	10-09-2003	Axonyx, Inc.
WO 03/101458 A1	12-11-2003	H. Lundbeck A/S

Other Documents

CHEN et al., Abstract, Memantine and the Processing of the Beta-Amyloid Precursor Protein, Society for Neuroscience, 2002, Online.

HARTMANN et al., Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy, International Clinical Psychopharmacology, 2003, pp. 81-85, Vol. 18.

WENK et al., No Interaction of Memantine with Acetylcholinesterase Inhibitors Approved for Clinical Use, Life Sciences, 2000, pp. 1079-83, Vol. 66, No. 12.

Supplementary European Search Report, EP 05 72 5930, dated August 23, 2007.

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: November 7, 2007

ACT/bv

Enclosures: Form PTO/SB/08

Cited Non-U.S. Patent Documents